Tarsus to Participate at Upcoming Virtual Investor Conferences
24 November 2021 - 8:30AM
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to
focus on unmet needs and apply proven science and new technology to
revolutionize treatment for patients, starting with eye care, today
announced that management will participate in the following virtual
investor conferences:
- Ophthalmology Day at BTIG on Tuesday, November 30, 2021
- Piper Sandler 33rd Annual Virtual Healthcare Conference on
December 1-2, 2021
The above listed dates are subject to change. Please check
www.tarsusrx.com for the latest information.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new
technology to revolutionize treatment for patients, starting with
eye care. It is advancing its pipeline to address several diseases
with high unmet need across a range of therapeutic categories,
including eye care, dermatology, and infectious disease prevention.
The company is studying two investigational medicines in clinical
trials. Its lead product candidate, TP-03, is a novel therapeutic
being studied in a second Phase 3 pivotal trial for the treatment
of Demodex blepharitis. TP-03 is also being developed for the
treatment of Meibomian Gland Disease. Tarsus is developing TP-05,
an oral, non-vaccine therapeutic for the prevention of Lyme
disease, which is currently being studied in a Phase 1 clinical
trial.
Contacts: Media Contact:SuJin Oh Shop PR(917)
841-5213sujin@shop-pr.com
Investor Contact:David NakasoneHead of Investor Relations(949)
620-3223DNakasone@tarsusrx.com
Tarsus Pharmaceuticals (NASDAQ:TARS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tarsus Pharmaceuticals (NASDAQ:TARS)
Historical Stock Chart
From Sep 2023 to Sep 2024